Once-weekly dual receptor agonist (GLP-1, GIP) for glucose control and weight loss, marketed as Mounjaro and Zepbound.
TR8CE uses one simple standard: 0.1 mL of bacteriostatic water per mg. A 5 mg vial takes 0.5 mL of water for a clean 10 mg/mL solution. Larger vials scale the water up to fit the glass.
| Vial size | BAC water | Concentration | 2.5 mg draws to |
|---|---|---|---|
| 5 mg | 0.5 mL | 10 mg/mL | 25 units |
| 10 mg | 1 mL | 10 mg/mL | 25 units |
| 15 mg | 1.5 mL | 10 mg/mL | 25 units |
| 20 mg | 2 mL | 10 mg/mL | 25 units |
| 30 mg | 3 mL | 10 mg/mL | 25 units |
| 40 mg | 4 mL | 10 mg/mL | 25 units |
| 60 mg | 6 mL | 10 mg/mL | 25 units |
Units are shown for a U-100 insulin syringe. A common starting dose is 2.5 mg. At 10 mg/mL, that draws to 25 units on a U-100 insulin syringe.
Dual agonism at the GLP-1 and GIP receptors regulates glucose and suppresses appetite, slowing gastric emptying and enhancing insulin response.
Tirzepatide is commonly taken in the morning.
Add 0.5 mL of bacteriostatic water to a 5 mg Tirzepatide vial for a 10 mg/mL solution.
A common Tirzepatide starting dose is 2.5 mg, which at 10 mg/mL draws to 25 units on a U-100 insulin syringe.
Draw bacteriostatic water into a syringe, inject it slowly down the inside glass of the Tirzepatide vial (not onto the powder), and swirl gently until clear. Store refrigerated and use within the common window.